{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T21:41:23Z","timestamp":1792014083182,"version":"4.4.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05699-8","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T08:04:31Z","timestamp":1774339471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mavacamten and atrial fibrillation: assessing the risk through FAERS and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Lingqing","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhang","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongkuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"5699_CR1","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jacc.2021.12.002","volume":"79","author":"BJ Maron","year":"2022","unstructured":"Maron BJ, Desai MY, Nishimura RA, et al. Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79:372\u201389. https:\/\/doi.org\/10.1016\/j.jacc.2021.12.002.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR2","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/S0735-1097(25)02015-7","volume":"85","author":"M Yildiz","year":"2025","unstructured":"Yildiz M, Muuse J, Schmidt C, et al. MAVACAMTEN AND ATRIAL FIBRILLATION RISK: INSIGHTS FROM A SINGLE-CENTER PROSPECTIVE STUDY. J Am Coll Cardiol. 2025;85:1531. https:\/\/doi.org\/10.1016\/S0735-1097(25)02015-7.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR3","doi-asserted-by":"publisher","first-page":"100622","DOI":"10.1016\/j.jacadv.2023.100622","volume":"2","author":"MS Mason Zhu","year":"2023","unstructured":"Mason Zhu MS, Klevin Roger L, Reyes MD, Gizem Bilgili MD, et al. Medical Therapies to Improve Left Ventricular Outflow Obstruction and Diastolic Function in Hypertrophic Cardiomyopathy. JACC Adv. 2023;2:100622. https:\/\/doi.org\/10.1016\/j.jacadv.2023.100622.","journal-title":"JACC Adv"},{"key":"5699_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.05.006","author":"MS Maron","year":"2009","unstructured":"Maron MS, Maron BJ, Harrigan C, et al. Hypertrophic Cardiomyopathy Phenotype Revisited After 50 Years With Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2009. https:\/\/doi.org\/10.1016\/j.jacc.2009.05.006.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR5","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R. (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 396, pg 759, 2020). LANCET 396:758\u2013758."},{"key":"5699_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jacc.2022.04.048","volume":"80","author":"MY Desai","year":"2022","unstructured":"Desai MY, Owens A, Geske JB, et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022;80:95\u2013108. https:\/\/doi.org\/10.1016\/j.jacc.2022.04.048.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR7","doi-asserted-by":"publisher","first-page":"A12764","DOI":"10.1161\/circ.148.suppl_1.12764","volume":"148","author":"N Patel","year":"2023","unstructured":"Patel N, Williams BR. Abstract 12764: Reduced EF With Mavacamten Initiation in a Patient With Atrial Fibrillation: A Case Report. Circulation. 2023;148:A12764\u201312764. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.12764.","journal-title":"Circulation"},{"key":"5699_CR8","doi-asserted-by":"publisher","first-page":"A19176","DOI":"10.1161\/circ.148.suppl_1.19176","volume":"148","author":"M jaikumar likhitesh, Biswas","year":"2023","unstructured":"jaikumar likhitesh, Biswas M, Kagan C, et al. Abstract 19176: Atrial Fibrillation Prevalence With Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Circulation. 2023;148:A19176\u201319176. https:\/\/doi.org\/10.1161\/circ.148.suppl_1.19176.","journal-title":"Circulation"},{"key":"5699_CR9","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/j.hrthm.2024.04.055","volume":"21","author":"M Castrichini","year":"2024","unstructured":"Castrichini M, Alsidawi S, Geske JB, et al. Incidence of newly recognized atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy treated with Mavacamten. Heart Rhythm. 2024;21:2065\u20137. https:\/\/doi.org\/10.1016\/j.hrthm.2024.04.055.","journal-title":"Heart Rhythm"},{"key":"5699_CR10","doi-asserted-by":"publisher","first-page":"null","DOI":"10.1007\/s00392-024-02496-1","volume":"31","author":"LW Liang","year":"2024","unstructured":"Liang LW, Lumish HS, Shimada YJ, Weiner SD. Incidence and recurrence of atrial fibrillation among patients with obstructive hypertrophic cardiomyopathy treated with mavacamten: a single-center experience. Clin Res Cardiol Published online July. 2024;31:null. https:\/\/doi.org\/10.1007\/s00392-024-02496-1.","journal-title":"Clin Res Cardiol Published online July"},{"key":"5699_CR11","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacep.2024.10.014","volume":"11","author":"TA Boyle","year":"2025","unstructured":"Boyle TA, Reza N, Hyman M, et al. Atrial Fibrillation in Patients Receiving Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Real-World Incidence, Management, and Outcomes. JACC Clin Electrophysiol. 2025;11:411\u20133. https:\/\/doi.org\/10.1016\/j.jacep.2024.10.014.","journal-title":"JACC Clin Electrophysiol"},{"key":"5699_CR12","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1001\/jamacardio.2023.3342","volume":"8","author":"MY Desai","year":"2023","unstructured":"Desai MY, Owens A, Wolski K, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: Week 56 Results From the VALOR-HCM Randomized Clinical Trial. JAMA Cardiol. 2023;8:968\u201377. https:\/\/doi.org\/10.1001\/jamacardio.2023.3342.","journal-title":"JAMA Cardiol"},{"key":"5699_CR13","doi-asserted-by":"publisher","first-page":"e536","DOI":"10.1016\/j.hrthm.2024.12.049","volume":"22","author":"P Hundal","year":"2025","unstructured":"Hundal P, Jan MF, Abood Z, et al. To the Editor \u2014 Impact of mavacamten on atrial fibrillation in patients with obstructive hypertrophic cardiomyopathy. Heart Rhythm. 2025;22:e536\u20137. https:\/\/doi.org\/10.1016\/j.hrthm.2024.12.049.","journal-title":"Heart Rhythm"},{"key":"5699_CR14","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1161\/CIRCULATIONAHA.123.065037","volume":"148","author":"EJ Rowin","year":"2023","unstructured":"Rowin EJ, Link MS, Maron MS, Maron BJ. Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation. 2023;148:1797\u2013811. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065037.","journal-title":"Circulation"},{"key":"5699_CR15","doi-asserted-by":"publisher","unstructured":"January CT, Wann LS, Calkins H, et al. 2019 AHA\/ACC\/HRS Focused Update of the 2014 AHA\/ACC\/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140. https:\/\/doi.org\/10.1161\/CIR.0000000000000665.","DOI":"10.1161\/CIR.0000000000000665"},{"key":"5699_CR16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1177\/1074248420984082","volume":"26","author":"LN Moreland-Head","year":"2021","unstructured":"Moreland-Head LN, Coons JC, Seybert AL, et al. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database. J Cardiovasc Pharmacol Ther. 2021;26:341\u20138. https:\/\/doi.org\/10.1177\/1074248420984082.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"5699_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10741-018-9752-6","volume":"24","author":"L Garg","year":"2019","unstructured":"Garg L, Gupta M, Sabzwari SRA, et al. Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management. Heart Fail Rev. 2019;24:189\u201397. https:\/\/doi.org\/10.1007\/s10741-018-9752-6.","journal-title":"Heart Fail Rev"},{"key":"5699_CR18","doi-asserted-by":"publisher","first-page":"e00474","DOI":"10.1016\/j.neurot.2024.e00474","volume":"22","author":"H Xiang","year":"2025","unstructured":"Xiang H, Ma Y, Luo X, et al. Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database. Neurother J Am Soc Exp Neurother. 2025;22:e00474. https:\/\/doi.org\/10.1016\/j.neurot.2024.e00474.","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"5699_CR19","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.jacc.2004.08.053","volume":"44","author":"S van der Hooft Cornelis","year":"2004","unstructured":"van der Hooft Cornelis S, Jan H, van Herpen, Gerard, et al. Drug-induced atrial fibrillation. JACC. 2004;44:2117\u201324. https:\/\/doi.org\/10.1016\/j.jacc.2004.08.053.","journal-title":"JACC"},{"key":"5699_CR20","doi-asserted-by":"crossref","unstructured":"Poluzzi E, Raschi E, Piccinni C et al. (2012) Data Mining Techniques in Pharmacovigilance: Analysis of the Publicly Accessible FDA Adverse Event Reporting System (AERS). In: Data Mining Applications in Engineering and Medicine. IntechOpen.","DOI":"10.5772\/50095"},{"key":"5699_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJW. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18:427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"5699_CR22","doi-asserted-by":"publisher","first-page":"e0264580","DOI":"10.1371\/journal.pone.0264580","volume":"17","author":"H-J Lee","year":"2022","unstructured":"Lee H-J, Kim H-K, Lee SC, et al. Age-related sex differences in the outcomes of patients with hypertrophic cardiomyopathy. PLoS ONE. 2022;17:e0264580. https:\/\/doi.org\/10.1371\/journal.pone.0264580.","journal-title":"PLoS ONE"},{"key":"5699_CR23","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1093\/eurheartj\/ehx527","volume":"38","author":"JB Geske","year":"2017","unstructured":"Geske JB, Ong KC, Siontis KC, et al. Women with hypertrophic cardiomyopathy have worse survival. Eur Heart J. 2017;38:3434\u201340. https:\/\/doi.org\/10.1093\/eurheartj\/ehx527.","journal-title":"Eur Heart J"},{"key":"5699_CR24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/jcpt.13024","volume":"45","author":"S Kinoshita","year":"2020","unstructured":"Kinoshita S, Hosomi K, Yokoyama S, Takada M. Time-to-onset analysis of amiodarone-associated thyroid dysfunction. J Clin Pharm Ther. 2020;45:65\u201371. https:\/\/doi.org\/10.1111\/jcpt.13024.","journal-title":"J Clin Pharm Ther"},{"key":"5699_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2165\/11599740-000000000-00000","volume":"35","author":"VR Cornelius","year":"2012","unstructured":"Cornelius VR, Sauzet O, Evans SJW. A signal detection method to detect adverse drug reactions using a parametric time-to-event model in simulated cohort data. Drug Saf. 2012;35:599\u2013610. https:\/\/doi.org\/10.2165\/11599740-000000000-00000.","journal-title":"Drug Saf"},{"key":"5699_CR26","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12916-024-03274-6","volume":"22","author":"J Zhou","year":"2024","unstructured":"Zhou J, Zheng Y, Xu B, et al. Exploration of the potential association between GLP-1 receptor agonists and suicidal or self-injurious behaviors: a pharmacovigilance study based on the FDA Adverse Event Reporting System database. BMC Med. 2024;22:65. https:\/\/doi.org\/10.1186\/s12916-024-03274-6.","journal-title":"BMC Med"},{"key":"5699_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","volume":"36","author":"O Sauzet","year":"2013","unstructured":"Sauzet O, Carvajal A, Escudero A, et al. Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data. Drug Saf. 2013;36:995\u20131006. https:\/\/doi.org\/10.1007\/s40264-013-0061-7.","journal-title":"Drug Saf"},{"key":"5699_CR28","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898.","journal-title":"BMJ"},{"key":"5699_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","volume":"25","author":"A Stang","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25:603\u20135. https:\/\/doi.org\/10.1007\/s10654-010-9491-z.","journal-title":"Eur J Epidemiol"},{"key":"5699_CR30","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/j.jacc.2020.03.064","volume":"75","author":"C Ho","year":"2020","unstructured":"Ho C, Mealiffe M, Bach R, et al. Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;75:2649\u201360. https:\/\/doi.org\/10.1016\/j.jacc.2020.03.064.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR31","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1001\/jamacardio.2023.3030","volume":"8","author":"Z Tian","year":"2023","unstructured":"Tian Z, Li L, Li X, et al. Effect of Mavacamten on Chinese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy: The EXPLORER-CN Randomized Clinical Trial. JAMA Cardiol. 2023;8:957\u201365. https:\/\/doi.org\/10.1001\/jamacardio.2023.3030.","journal-title":"JAMA Cardiol"},{"key":"5699_CR32","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jchf.2024.11.013","volume":"13","author":"MY Desai","year":"2025","unstructured":"Desai MY, Nissen SE, Abraham T, et al. Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Design, Rationale, and Baseline Characteristics of ODYSSEY-HCM. JACC Heart Fail. 2025;13:358\u201370. https:\/\/doi.org\/10.1016\/j.jchf.2024.11.013.","journal-title":"JACC Heart Fail"},{"key":"5699_CR33","doi-asserted-by":"publisher","unstructured":"Patel N, Gaonkar M, Pampana A, et al. Clinical Outcomes With Mavacamten Use in Patients With Obstructive Hypertrophic Cardiomyopathy Using Real-World Data. Mayo Clin Proc. 2025;1\u201311. https:\/\/doi.org\/10.1016\/j.mayocp.2025.01.003.","DOI":"10.1016\/j.mayocp.2025.01.003"},{"key":"5699_CR34","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1136\/heartjnl-2013-304276","volume":"100","author":"OP Guttmann","year":"2014","unstructured":"Guttmann OP, Rahman MS, O\u2019Mahony C, et al. Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart Br Card Soc. 2014;100:465\u201372. https:\/\/doi.org\/10.1136\/heartjnl-2013-304276.","journal-title":"Heart Br Card Soc"},{"key":"5699_CR35","doi-asserted-by":"publisher","first-page":"e004052","DOI":"10.1161\/CIRCEP.116.004052","volume":"10","author":"P Debonnaire","year":"2017","unstructured":"Debonnaire P, Joyce E, Hiemstra Y, et al. Left Atrial Size and Function in Hypertrophic Cardiomyopathy Patients and Risk of New-Onset Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2017;10:e004052. https:\/\/doi.org\/10.1161\/CIRCEP.116.004052.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"5699_CR36","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.echo.2004.02.010","volume":"17","author":"T Tani","year":"2004","unstructured":"Tani T, Tanabe K, Ono M, et al. Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2004;17:644\u20138. https:\/\/doi.org\/10.1016\/j.echo.2004.02.010.","journal-title":"J Am Soc Echocardiogr"},{"key":"5699_CR37","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1016\/j.jcmg.2023.06.008","volume":"16","author":"P Wessly","year":"2023","unstructured":"Wessly P, Lazzara GE, Buergler JM, Nagueh SF. Early Observations on Effects of Mavacamten on Left Atrial Function in Obstructive Hypertrophic Cardiomyopathy Patients. JACC Cardiovasc Imaging. 2023;16:1633\u20134. https:\/\/doi.org\/10.1016\/j.jcmg.2023.06.008.","journal-title":"JACC Cardiovasc Imaging"},{"key":"5699_CR38","doi-asserted-by":"publisher","first-page":"i421","DOI":"10.1093\/ehjci\/jeae333.270","volume":"26","author":"B Ozbay","year":"2025","unstructured":"Ozbay B, Venkatesan N, Wong TC, Sade LE. Effects of mavacamten on left atrial function in hypertrophic obstructive cardiomyopathy. Eur Heart J Cardiovasc Imaging. 2025;26:i421. https:\/\/doi.org\/10.1093\/ehjci\/jeae333.270.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"5699_CR39","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s40256-022-00532-x","volume":"22","author":"JM Edelberg","year":"2022","unstructured":"Edelberg JM, Sehnert AJ, Mealiffe ME, et al. The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review. Am J Cardiovasc Drugs Drugs Devices Interv. 2022;22:497\u2013510. https:\/\/doi.org\/10.1007\/s40256-022-00532-x.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"5699_CR40","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1016\/j.jacc.2021.09.1381","volume":"78","author":"S Hegde","year":"2021","unstructured":"Hegde S, Lester S, Solomon S, et al. Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2021;78:2518\u201332. https:\/\/doi.org\/10.1016\/j.jacc.2021.09.1381.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR41","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1016\/j.cardfail.2023.11.009","volume":"30","author":"J Muuse","year":"2024","unstructured":"Muuse J, Patel K, Price C, et al. Left Atrial Functional Assessment in Hypertrophic Cardiomyopathy Patients Receiving Mavacamten. J Card Fail. 2024;30:S5. https:\/\/doi.org\/10.1016\/j.cardfail.2023.11.009.","journal-title":"J Card Fail"},{"key":"5699_CR42","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1161\/CIRCULATIONAHA.120.052359","volume":"143","author":"S Saberi","year":"2021","unstructured":"Saberi S, Cardim N, Yamani M, et al. Mavacamten Favorably Impacts Cardiac Structure in Obstructive Hypertrophic Cardiomyopathy: EXPLORER-HCM Cardiac Magnetic Resonance Substudy Analysis. Circulation. 2021;143:606\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.052359.","journal-title":"Circulation"},{"key":"5699_CR43","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.3390\/biomedicines13041005","volume":"13","author":"A Badr","year":"2025","unstructured":"Badr A, Roehl K, Suppah M, et al. Temporal Patterns of Holter-Detected Arrhythmias in Hypertrophic Cardiomyopathy Patients Treated with Mavacamten. Biomedicines. 2025;13:1005. https:\/\/doi.org\/10.3390\/biomedicines13041005.","journal-title":"Biomedicines"},{"key":"5699_CR44","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0735-1097(25)00504-2","volume":"85","author":"J Schmeckpeper","year":"2025","unstructured":"Schmeckpeper J, Kim K, Willits C, MAVACAMTEN-LIKE CARDIAC MYOSIN INHIBITOR MYK-581 REDUCES RISK OF ATRIAL FIBRILLATION INDUCTION IN MURINE MODEL OF HYPERTROPHIC CARDIOMYOPATHY. J Am Coll Cardiol. 2025;85:19. https:\/\/doi.org\/10.1016\/S0735-1097(25)00504-2.","journal-title":"J Am Coll Cardiol"},{"key":"5699_CR45","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Oreziak A, Choudhury L, et al. Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: interim Results From the MAVA-LTE Study, EXPLORER-LTE Cohort. JACC Heart Fail. 2024;12:164\u201377. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.028.","journal-title":"JACC Heart Fail"},{"key":"5699_CR46","doi-asserted-by":"publisher","first-page":"e033767","DOI":"10.1161\/JAHA.124.033767","volume":"13","author":"AT Owens","year":"2024","unstructured":"Owens AT, Desai M, Wheeler MT, et al. Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response. J Am Heart Assoc. 2024;13:e033767. https:\/\/doi.org\/10.1161\/JAHA.124.033767.","journal-title":"J Am Heart Assoc"},{"key":"5699_CR47","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s40256-024-00672-2","volume":"24","author":"Z Yukselen","year":"2024","unstructured":"Yukselen Z, Raju AKV, Kumar PA, et al. A Real\u2013World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten. Am J Cardiovasc Drugs Drugs Devices Interv. 2024;24:791\u20139. https:\/\/doi.org\/10.1007\/s40256-024-00672-2.","journal-title":"Am J Cardiovasc Drugs Drugs Devices Interv"},{"key":"5699_CR48","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1161\/CIRCULATIONAHA.124.072445","volume":"151","author":"M Desai","year":"2025","unstructured":"Desai M, Wolski K, Owens A, et al. Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal Reduction: week 128 Results from VALOR-HCM. Circulation. 2025;151:1378\u201390. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.124.072445.","journal-title":"Circulation"},{"key":"5699_CR49","doi-asserted-by":"publisher","first-page":"101467","DOI":"10.1016\/j.ijcha.2024.101467","volume":"53","author":"I Ullah","year":"2024","unstructured":"Ullah I, Tayyaba Rehan S, Khan Z, et al. Efficacy and safety of Mavacamten for symptomatic Hypertrophic cardiomyopathy \u2013 an updated Meta-Analysis of randomized controlled trials. IJC Heart Vasc. 2024;53:101467. https:\/\/doi.org\/10.1016\/j.ijcha.2024.101467.","journal-title":"IJC Heart Vasc"},{"key":"5699_CR50","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10741-023-10375-6","volume":"29","author":"MS Yacoub","year":"2023","unstructured":"Yacoub MS, El-Nakhal T, Hasabo EA, et al. A systematic review and meta-analysis of the efficacy and safety of Mavacamten therapy in international cohort of 524 patients with hypertrophic cardiomyopathy. Heart Fail Rev. 2023;29:479\u201396. https:\/\/doi.org\/10.1007\/s10741-023-10375-6.","journal-title":"Heart Fail Rev"},{"key":"5699_CR51","doi-asserted-by":"publisher","first-page":"133846","DOI":"10.1016\/j.ijcard.2025.133846","volume":"442","author":"M Shawki","year":"2026","unstructured":"Shawki M, Rodrigues T, Khabazi K, et al. Short-term incidence and risk of atrial fibrillation in patients with hypertrophic cardiomyopathy receiving cardiac myosin inhibitors: A systematic review and meta-analysis. Int J Cardiol. 2026;442:133846. https:\/\/doi.org\/10.1016\/j.ijcard.2025.133846.","journal-title":"Int J Cardiol"},{"key":"5699_CR52","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1136\/heartjnl-2016-309672","volume":"103","author":"OP Guttmann","year":"2017","unstructured":"Guttmann OP, Pavlou M, O\u2019Mahony C, et al. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart Br Card Soc. 2017;103:672\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2016-309672.","journal-title":"Heart Br Card Soc"},{"key":"5699_CR53","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jchf.2025.02.005","volume":"13","author":"MY Desai","year":"2025","unstructured":"Desai MY, Saberi S, Geske JB, et al. Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex: Insights From the VALOR-HCM Trial. JACC Heart Fail. 2025;13:1037\u201340. https:\/\/doi.org\/10.1016\/j.jchf.2025.02.005.","journal-title":"JACC Heart Fail"},{"key":"5699_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1161\/CIRCULATIONAHA.123.065600","volume":"149","author":"S Cresci","year":"2024","unstructured":"Cresci S, Bach RG, Saberi S, et al. Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation. 2024;149:498\u2013509. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065600.","journal-title":"Circulation"},{"key":"5699_CR55","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/j.cardfail.2024.10.449","volume":"31","author":"A Wang","year":"2025","unstructured":"Wang A, Lakdawala N, Abraham T, et al. Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial. J Card Fail. 2025;31:901\u201311. https:\/\/doi.org\/10.1016\/j.cardfail.2024.10.449.","journal-title":"J Card Fail"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05699-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:19:55Z","timestamp":1777601995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5699"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05699-8","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study utilized publicly available anonymized data from the FDA Adverse Event Reporting System (FAERS) and the information within these analyses does not allow patient\u2019s identification. The meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"378"}}